-
DE
Thrombomodulin is a glycoprotein on the surface of vascular endothelial cells that plays a key role in inhibiting blood coagulation and regulating inflammation.
Thrombomodulin is a glycoprotein on the surface of vascular endothelial cells that plays a key role in inhibiting blood coagulation and regulating inflammation.
Thrombomodulin (also known as CD141 or BDCA-3) is a transmembrane glycoprotein expressed primarily on the surface of endothelial cells – the cells lining the inner walls of blood vessels. It acts as a critical natural anticoagulant and plays a central role in maintaining the balance between clot formation and clot inhibition in the bloodstream.
Thrombomodulin works by binding thrombin – a key enzyme in blood coagulation – and fundamentally altering its function. Under normal circumstances, thrombin promotes clotting by converting fibrinogen to fibrin and activating platelets. However, when thrombin binds to thrombomodulin, it loses these procoagulant properties and acquires new anticoagulant functions:
Thrombomodulin has considerable clinical relevance across a range of diseases and pathological conditions:
Reduced expression or impaired function of thrombomodulin on endothelial cells can increase the risk of thrombosis. Mutations in the thrombomodulin gene (THBD) have been associated with an elevated risk of venous thromboembolism (blood clots in veins), myocardial infarction, and stroke.
In disseminated intravascular coagulation – a life-threatening disorder characterized by simultaneous excessive clotting and bleeding – thrombomodulin function is severely compromised. A recombinant thrombomodulin preparation (thrombomodulin alfa) is approved in Japan for the treatment of DIC and is under investigation in clinical trials in other countries.
In severe sepsis (life-threatening infection), thrombomodulin is shed from the endothelial surface, contributing to increased coagulation activity and systemic inflammation. Soluble thrombomodulin in the blood therefore serves as a biomarker for endothelial injury and sepsis severity.
Thrombomodulin is also implicated in thrombotic microangiopathy (TMA), a group of disorders characterized by damage to small blood vessels. Mutations in the THBD gene have been described in patients with hemolytic uremic syndrome (HUS).
Soluble thrombomodulin released into the circulation following endothelial injury can be measured in laboratory tests and serves as a marker of endothelial dysfunction. Elevated levels are observed in sepsis, diabetes mellitus, cardiovascular disease, and after organ transplantation.
Based on the anticoagulant and anti-inflammatory properties of thrombomodulin, recombinant preparations have been developed for clinical use:
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.